P C de Jong
Overview
Explore the profile of P C de Jong including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Boo L, Jozwiak K, Ter Hoeve N, van Diest P, Opdam M, Wang Y, et al.
ESMO Open
. 2024 Mar;
9(3):102923.
PMID: 38452438
Background: In the absence of prognostic biomarkers, most patients with early-stage triple-negative breast cancer (eTNBC) are treated with combination chemotherapy. The identification of biomarkers to select patients for whom treatment...
2.
Opdam M, van der Noort V, Kleijn M, Glas A, Mandjes I, Kleiterp S, et al.
Breast Cancer Res Treat
. 2022 May;
194(2):265-278.
PMID: 35587322
Purpose: Guidelines recommend endocrine treatment for estrogen receptor-positive (ER+) breast cancers for up to 10 years. Earlier data suggest that the 70-gene signature (MammaPrint) has potential to select patients that...
3.
Bouwer N, Steenbruggen T, van Rosmalen J, Rier H, Kitzen J, van Bekkum M, et al.
Breast Cancer Res Treat
. 2021 Jan;
186(3):851-862.
PMID: 33394273
Purpose: Patients with HER2-positive metastatic breast cancer (MBC) usually receive many years of trastuzumab treatment. It is unknown whether these patients require continuous left ventricular ejection fraction (LVEF) monitoring. We...
4.
van den Brand A, Rubinstein E, de Jong P, van den Berg M, van Duursen M
Reprod Toxicol
. 2020 Jul;
96:202-208.
PMID: 32668270
Unopposed estrogenic action in the uterus can lead to the development of endometrial cancer in both humans and rats. Aryl hydrocarbon receptor (AHR) activation gives rise to anti-estrogenic actions and...
5.
Steenbruggen T, Bouwer N, Smorenburg C, Rier H, Jager A, Beelen K, et al.
Breast Cancer Res Treat
. 2019 Sep;
178(3):597-605.
PMID: 31493033
Purpose: Patients with HER2-positive metastatic breast cancer (MBC) treated with trastuzumab may experience durable tumor response for many years. It is unknown if patients with durable radiological complete remission (rCR)...
6.
van den Brand A, Rubinstein E, de Jong P, van den Berg M, van Duursen M
J Steroid Biochem Mol Biol
. 2019 Aug;
194:105458.
PMID: 31465845
Human and rat reproductive systems differ significantly with respect to hormonal cyclicity and endometrial cell behavior. However, species-differences in endometrial cell responses upon hormonal stimulation and exposure to potentially toxic...
7.
Schraa S, Frerichs K, Agterof M, Hunting J, Los M, de Jong P
Eur J Cancer
. 2017 May;
79:152-157.
PMID: 28494406
Aim: Adjuvant chemotherapy treatment of women with breast cancer is frequently complicated by toxic side-effects, resulting in dose reduction and delay. In Dutch guidelines, a relative dose intensity (RDI) of...
8.
Busweiler L, Schouwenburg M, van Berge Henegouwen M, Kolfschoten N, de Jong P, Rozema T, et al.
Br J Surg
. 2017 Feb;
104(6):742-750.
PMID: 28240357
Background: Quality assurance is acknowledged as a crucial factor in the assessment of oncological surgical care. The aim of this study was to develop a composite measure of multiple outcome...
9.
de Jong P
Bull Anesth Hist
. 2012 Aug;
28(3):37, 40-2.
PMID: 22849205
The Second World War brought much grief to the world. Roermond was at the forefront of the war for a period of five months. Before the war, in this part...
10.
Meulenbeld H, van Werkhoven E, Coenen J, Creemers G, Loosveld O, de Jong P, et al.
Eur J Cancer
. 2012 Jun;
48(16):2993-3000.
PMID: 22677260
Background: This multicentre, randomised, open label, phase II/III study aimed to investigate the potential benefit of adding risedronate (R) to docetaxel (D) in patients with metastatic Castration Resistant Prostate Cancer...